Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y. · 2014

Read Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. by Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4177084.txt.

Introduction

Osamu Tohyama, Yasuhiro Funahashi, and seven co-authors tested the drug lenvatinib in thyroid cancer models in the Journal of Thyroid Research in 2014. Lenvatinib blocks several receptor proteins that tumours use to grow new blood vessels and to drive their own growth. Thyroid cancers that no longer respond to standard care have few options.

Given by mouth to mice carrying human thyroid tumours, lenvatinib shrank growth in five differentiated, five anaplastic, and one medullary tumour models, and it cut vessel growth in most of them. In dishes it stopped growth directly in only two of eleven cell lines, one with high FGFR1 and one with a mutant RET protein, both targets of the drug. The main effect, the team concludes, is starving the tumour of blood flow.

Catalog record

CREATORTohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4177084

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models By Osamu Tohyama, Junji Matsui, Kotaro Kodama, Naoko Hata-Sugi, Takayuki Kimura, Kiyoshi Okamoto, Yukinori Minoshima, Masao Iwata, Yasuhiro Funahashi Published in: Journal of Thyroid Research DOI: 10.1155/2014/638747 ABSTRACT Abstract Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1–4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models. 1. INTRODUCTION Thyroid cancer is a common malignant endocrine tumor, the incidence of which has recently been increasing. More than 90% of thyroid cancers are the follicular or papillary types known as differentiated thyroid cancer (DTC) [1], which comprises 1% of all cancers globally. Ninety percent of patients with DTC survive at least 10 years [2]; however, DTC patients with radioactive iodine- (RAI-) refractory disease have a median survival of 2.5 to 3.5 years from detection of distant metastases [3, 4]. The cytotoxic agents used to treat RAI refractory disease have been universally classified as having only marginal efficacy and substantial toxicity [5, 6]. Approximately 10% of all thyroid cancers are medullary thyroid cancer (MTC) [7], which is a distinct C-cell tumor of the thyroid. MTC occurs in both sporadic (75% of patients) and hereditary settings, and the latter includes three distinct inherited cancer syndromes: familial MTC, multiple endocrine neoplasia type 2A (MEN2A), and MEN2B [8]. MTC is associated with a favorable prognosis (i.e., 10-year survival rate, ~70%) in the case that the disease is treated at an early stage, but the prognosis is poor (i.e., 10-year survival rate, <50%) in patients with distant metastatic disease [9]. Anaplastic thyroid cancer (ATC) remains one of the most deadly human diseases but accounts for fewer than 2% of all thyroid cancers [10, 11]. Average survival after diagnosis is only 4 to 6 months [10, 12], and the tumor is usually well advanced by the time of diagnosis. ATC tumors are generally resistant to chemotherapy, and currently there is no effective therapeutic regimen for the treatment of ATC. Various genetic alterations participate in the tumorigenesis of thyroid cancer [13]. BRAF V600E is one of the most frequent mutations, occurring in approximately 45% of papillary thyroid cancers (PTCs) [14] and 26% of ATCs [14, 15]. Other genetic alterations in PTC are point mutations in RAS [13, 16] and rearrangement of RET [17]. In follicular thyroid carcinoma (FTC), mutations in RAS [18, 19] and rearrangement of the PPARγ and PAX8 genes [18] are also common. Germline mutations in the RET proto-oncogene cause hereditary MTC [20–22], and approximately 50% of patients with sporadic MTC have somatic RET mutations [23, 24]. Accordingly, new molecularly targeted therapies are needed for the treatment of thyroid cancer. Tumor angiogenesis—the formation of blood vessels within tumors—plays a key role in cancer cell survival, local tumor growth, and the development of distant metastases [25–28]. Numerous angiogenic factors have been identified, including VEGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor, interleukin-8, and PDGF. VEGF is a crucial regulator of both physiologic and pathologic angiogenesis via its binding to the cognate receptor VEGFR2. Since increased VEGF expression is significantly associated with advanced-stage thyroid cancer [29], the use of inhibitors against VEGFR2 signaling pathway may represent a viable approach to controlling malignant thyroid cancer [30]. Inhibitors of the VEGFR2 signaling pathway show antitumor activity against various types of tumors, and consequently many of them are now in clinical use [31]. In phase 2 clinical trials of thyroid cancers motesanib, axitinib, and pazopanib, which are multiple receptor-tyrosine kinase inhibitors, have shown promising antitumor activity [32]. The US FDA recently approved sorafenib for the treatment of patients with locally recurrent or metastatic, progressive DTC that is refractory to RAI treatment [33]. Vandetanib [34] and cabozantinib have been approved for use in the treatment of advanced or metastatic MTC. Therefore, molecularly targeted agents for the VEGFR2 signaling pathway are expected as new thyroid cancer therapy. Beside VEGFR2 signaling pathway, other receptor tyrosine kinases (RTKs) have significant roles in thyroid cancer. Overexpression of fibroblast growth factor receptor [35] and mutations of RET [23, 24] are reported to participate in the development and aggressive phenotypes of thyroid cancers. Given that the most of VEGFR2 inhibitors which target multiple receptors, inhibition of those RTKs could improve thyroid cancer therapy in addition to targeting the VEGFR2 signaling pathway. Lenvatinib mesilate (lenvatinib) inhibits the multiple RTKs that target VEGF receptors (VEGFR1–3), FGF receptors (FGFR1–4), PDGF receptor α (PDGFRα), KIT, and RET [36]. Besides its antiangiogenesis activity based on VEGFR2 inhibition [36], lenvatinib has also shown antitumor activity based on inhibition of RET phosphorylation in PTC carrying RET/PCT fusion genes [37]. Lenvatinib has shown antitumor activity against multiple tumor types, such as DTC, MTC, melanoma, endometrial and hepatocellular [38, 39]. The purpose of this study was to assess the antitumor activity of lenvatinib and explore its mode of action in preclinical human thyroid cancer models, using DTC, MTC, and ATC cell lines. Here, we describe how lenvatinib inhibited in vivo tumor growth and tumor-induced angiogenesis in various human thyroid cancer xenograft models. We also show that lenvatinib directly inhibits the in vitro proliferation of thyroid cancer cell lines carrying mutations that activate RET or in which FGFR1 is overexpressed. 2. MATERIALS AND METHODS 2.1. Compounds Lenvatinib mesilate (lenvatinib), PD166866, PD173074, imatinib, and Ki6783 were synthesized at Eisai Co., Ltd. (Ibaraki, Japan). Sorafenib was purchased from Bayer (Tokyo, Japan). 2.2. Cell Free Kinase Inhibition Assay The kinase inhibitory activities of lenvatinib and sorafenib against 66 purified recombinant protein kinases (including tyrosine kinases and serine threonine kinases) were examined by using an ELISA and an Off-Chip Mobility Shift Assay (MSA) from Carna Biosciences, Inc. (Kobe, Japan). Briefly, each test compound was mixed with enzyme, substrate, ATP, and Mg under appropriate buffer conditions for the ELISA or MSA. The readout value of the reaction control (complete reaction mixture) was set as 0% inhibition, and the readout value of the background (Enzyme (−)) was set as 100% inhibition; the percent inhibition of each test solution was then calculated. IC50 values (the half maximal inhibitory concentration) were calculated from concentrations versus % inhibition curves. 2.3. Cells The human DTC cell lines K1,

Read the complete text